Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by UMB Bank n.a.

UMB Bank n.a. lifted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 68.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 940 shares of the medical equipment provider’s stock after acquiring an additional 381 shares during the period. UMB Bank n.a.’s holdings in Lantheus were worth $92,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Kestra Investment Management LLC bought a new position in Lantheus during the fourth quarter valued at about $27,000. Summit Securities Group LLC acquired a new position in shares of Lantheus in the 4th quarter valued at $37,000. Parkside Financial Bank & Trust boosted its position in shares of Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock valued at $76,000 after purchasing an additional 280 shares during the period. 1620 Investment Advisors Inc. purchased a new stake in Lantheus in the 4th quarter worth about $125,000. Finally, Daiwa Securities Group Inc. purchased a new stake in Lantheus in the 4th quarter worth about $136,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on LNTH shares. B. Riley cut their price target on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Truist Financial cut their price objective on Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Finally, Wall Street Zen raised Lantheus from a “hold” rating to a “buy” rating in a report on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $132.67.

Insider Transactions at Lantheus

In related news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the sale, the director now owns 318,650 shares of the company’s stock, valued at $24,481,879.50. This represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07% decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is owned by corporate insiders.

Lantheus Stock Performance

LNTH opened at $80.14 on Friday. Lantheus Holdings, Inc. has a 52-week low of $73.11 and a 52-week high of $126.89. The firm has a market capitalization of $5.54 billion, a PE ratio of 13.33 and a beta of 0.11. The business’s 50-day simple moving average is $89.13 and its 200 day simple moving average is $91.46.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). The firm had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Lantheus’s revenue for the quarter was up .8% on a year-over-year basis. During the same quarter last year, the business posted $1.69 EPS. On average, research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.